Scholarlink

<p>Brucellosis is a widespread and persistent zoonotic disease caused by Gram-negative <i>Brucella</i> species, posing significant threats to human health, livestock, and economic stability. This review provides a comprehensive insight into current knowledge on <i>Brucella</i> pathogenicity, genomic structure and therapeutic challenges. We highlight the host-specific pathogenic mechanism of predominated species as <i>B. melitensis</i>, <i>B. abortus</i>, <i>B. suis</i> and <i>B. canis</i> focusing on their bipartite genome organization, virulence factors and strategies for intracellular survival and immune evasion. Diagnostic approaches including serological assays, such as SAT, ELISA, and molecular techniques like PCR molecular techniques are critically evaluated, alongside current antibiotic regimens and their limitations due to resistance and relapse. We further discuss promising developments in vaccine research—such as live attenuated, subunit, and DNA-based platforms—as well as adjunctive therapies involving nanotechnology, herbal compounds, and novel antibiotics. Emphasis is placed on the integration of genomic insights with therapeutic innovation. We conclude by identifying key research priorities, including the need for improved diagnostics, resistance profiling, and next-generation vaccines. This review underscores the importance of a multidisciplinary approach to mitigate the global burden of brucellosis and advance translational research in prevention and treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Brucellosis in the omics era: integrative perspectives on Brucella genomic architecture, host-pathogen interactions, and disease dynamics

  • 期刊论文

  • 发表日期：

    2025年7月11日

查看全文
  • Shashi Bhushan Kumar,
  • Giridhar Goudar,
  • Manne Munikumar,
  • Shanvanth R. Arnipalli,
  • Puneeta Singh Yaduvanshi,
  • Virendra V. Panpatil

摘要

Brucellosis is a widespread and persistent zoonotic disease caused by Gram-negative Brucella species, posing significant threats to human health, livestock, and economic stability. This review provides a comprehensive insight into current knowledge on Brucella pathogenicity, genomic structure and therapeutic challenges. We highlight the host-specific pathogenic mechanism of predominated species as B. melitensis, B. abortus, B. suis and B. canis focusing on their bipartite genome organization, virulence factors and strategies for intracellular survival and immune evasion. Diagnostic approaches including serological assays, such as SAT, ELISA, and molecular techniques like PCR molecular techniques are critically evaluated, alongside current antibiotic regimens and their limitations due to resistance and relapse. We further discuss promising developments in vaccine research—such as live attenuated, subunit, and DNA-based platforms—as well as adjunctive therapies involving nanotechnology, herbal compounds, and novel antibiotics. Emphasis is placed on the integration of genomic insights with therapeutic innovation. We conclude by identifying key research priorities, including the need for improved diagnostics, resistance profiling, and next-generation vaccines. This review underscores the importance of a multidisciplinary approach to mitigate the global burden of brucellosis and advance translational research in prevention and treatment.